Search for: "Warner Chilcott Pharmaceuticals Inc." Results 1 - 20 of 29
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Dec 2011, 9:59 pm by Patent Docs
Mylan Pharmaceuticals Inc., an ANDA case brought before Judge Martini in the New Jersey District Court. [read post]
11 Apr 2010, 9:36 pm by Patent Docs
Mylan Pharmaceuticals Inc. 1:10-cv-00285; filed April 8, 2010 in the District Court of Delaware • Plaintiffs: Warner Chilcott Co. [read post]
31 Dec 2015, 8:16 pm by Patent Docs
Teva Pharmaceuticals USA, Inc. et al. 1:15-cv-00761; filed August 31, 2015 in the District Court of Delaware • Plaintiffs: Warner Chilcott (US), LLC; Warner Chilcott Co., LLC; Qualicaps Co., Ltd. [read post]
13 Sep 2009, 9:31 pm
Warner Chilcott C. [read post]
29 Aug 2011, 7:56 am by Sonya Hubbard
Prior to that, he spent 17 years with Warner-Lambert, which is now part of Pfizer, Inc. [read post]
9 Nov 2021, 2:54 pm by greggshapiro.admin
Prior authorization requirements are a common hurdle to increased drug sales and, as the earlier cases against Warner-Chilcott and Insys show, pharmaceutical companies have an incentive to overcome those requirements, sometimes by fraud. [read post]
25 Jul 2011, 10:48 am by admin
., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release tablets, and ACTONEL WITH CALCIUM (Copackaged) (risedronate sodium with calcium carbonate) tablets, Warner Chilcott, LLC; BONIVA (ibandronate sodium) tablets and injection, Roche Therapeutics, Inc.; RECLAST (zoledronic acid) injection, Novartis Pharmaceuticals Corp.; and the generic equivalents for these products, if any. [read post]
24 Dec 2008, 3:00 pm
Apotex, Inc (Managing Intellectual Property)     [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent term adjustment… [read post]
8 Sep 2011, 11:04 am by Tom Lamb
According to the FDA's Announcement for this September 2011 meeting, these two advisory committees will consider the benefits and risks of long-term use of osteoporosis medications in the bisphosphonate class of drugs, which were identified by the FDA as: FOSAMAX (alendronate sodium) tablets and solution and FOSAMAX PLUS D (alendronate sodium/cholecalciferol) tablets, Merck & Co., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release… [read post]